Comparison · NCT03808688-sae
Netarsudil Ophthalmic Solution 0.02% Monotherapy vs Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Netarsudil Ophthalmic Solution 0.02% Monotherapy vs Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy: serious adverse events. Trial comparisons, record NCT03808688-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03808688-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0202 | 0.00556 | 0.0707 | wilson | |
| Risk in group 2 | 0.00621 | 0.0011 | 0.0343 | wilson | |
| Risk difference, group 1 minus group 2 | 0.014 | -0.0177 | 0.0647 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.25 | 0.299 | 35.4 | log | |
| Odds ratio, group 1 over group 2 | 3.3 | 0.295 | 36.9 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Netarsudil Ophthalmic Solution 0.02% Monotherapy than on Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy | 71.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Netarsudil Ophthalmic Solution 0.02% Monotherapy | Netarsudil Ophthalmic Solution 0.02% Monotherapy. 1 drop in each eye once daily in the evening. | 2 | 99 | EG000 |
| Group 2 | Netarsudil Ophthalmic Solution 0.02% Concomitant Therapy | Netarsudil Ophthalmic Solution 0.02% - Used Concomitantly With Other IOP Lowering Agents (2-5 total agents used). 1 drop in each eye once daily in the evening. | 1 | 161 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse event data was collected during the course of the 12-week treatment period.
Source ClinicalTrials.gov
Trial
- Title
- Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting
- NCT number
- NCT03808688
- Phases
- PHASE4
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- Netarsudil Ophthalmic Solution 0.02%
- Lead sponsor
- Aerie Pharmaceuticals
- Results first posted
- 2020-09-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03808688?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03808688-sae